Does CANAKINUMAB Cause Bronchopulmonary aspergillosis? 10 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Bronchopulmonary aspergillosis have been filed in association with CANAKINUMAB (Ilaris). This represents 0.1% of all adverse event reports for CANAKINUMAB.
10
Reports of Bronchopulmonary aspergillosis with CANAKINUMAB
0.1%
of all CANAKINUMAB reports
4
Deaths
6
Hospitalizations
How Dangerous Is Bronchopulmonary aspergillosis From CANAKINUMAB?
Of the 10 reports, 4 (40.0%) resulted in death, 6 (60.0%) required hospitalization, and 4 (40.0%) were considered life-threatening.
Is Bronchopulmonary aspergillosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CANAKINUMAB. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does CANAKINUMAB Cause?
Pyrexia (1,327)
Inappropriate schedule of drug administration (1,238)
Drug ineffective (1,078)
Inappropriate schedule of product administration (944)
Pain (858)
Condition aggravated (771)
Malaise (684)
Off label use (557)
Arthralgia (555)
Rash (505)
What Other Drugs Cause Bronchopulmonary aspergillosis?
TACROLIMUS (968)
PREDNISONE (967)
DEXAMETHASONE (854)
CYCLOPHOSPHAMIDE (824)
METHYLPREDNISOLONE (794)
PREDNISOLONE (704)
MYCOPHENOLATE MOFETIL (702)
RITUXIMAB (606)
CYCLOSPORINE (583)
METHOTREXATE (553)
Which CANAKINUMAB Alternatives Have Lower Bronchopulmonary aspergillosis Risk?
CANAKINUMAB vs CANDESARTAN
CANAKINUMAB vs CANDESARTAN CILEXETIL
CANAKINUMAB vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE
CANAKINUMAB vs CANGRELOR
CANAKINUMAB vs CANIS LUPUS FAMILIARIS SKIN